[go: up one dir, main page]

ES2330071B1 - COMBINATION OF ACTIVE SUBSTANCES. - Google Patents

COMBINATION OF ACTIVE SUBSTANCES. Download PDF

Info

Publication number
ES2330071B1
ES2330071B1 ES200800079A ES200800079A ES2330071B1 ES 2330071 B1 ES2330071 B1 ES 2330071B1 ES 200800079 A ES200800079 A ES 200800079A ES 200800079 A ES200800079 A ES 200800079A ES 2330071 B1 ES2330071 B1 ES 2330071B1
Authority
ES
Spain
Prior art keywords
combination
active substances
substances
active
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200800079A
Other languages
Spanish (es)
Other versions
ES2330071A1 (en
Inventor
Maria Angeles Fisas Escasany
Helmut H. Buschmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07384007A external-priority patent/EP1946777A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2330071A1 publication Critical patent/ES2330071A1/en
Application granted granted Critical
Publication of ES2330071B1 publication Critical patent/ES2330071B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinación de sustancias activas.Combination of active substances.

La presente invención se refiere a una combinación de sustancias activas que comprende al menos un compuesto de pirazolina sustituida y al menos un fármaco, conocido por producir ganancia de peso como un efecto secundario, un medicamento que comprende dicha combinación de sustancias activas, una formulación farmacéutica que comprende dicha combinación de sustancias activas y el uso de dicha combinación de sustancias activas para la fabricación de un medicamento.The present invention relates to a combination of active substances comprising at least one substituted pyrazoline compound and at least one drug, known for producing weight gain as a side effect, a medicament comprising said combination of active substances, a pharmaceutical formulation comprising said combination of active substances and the use of said combination of substances active for the manufacture of a medicine.

ES200800079A 2007-01-15 2008-01-14 COMBINATION OF ACTIVE SUBSTANCES. Expired - Fee Related ES2330071B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07000745 2007-01-15
EP07000745 2007-01-15
EP07384007 2007-01-16
EP07384007A EP1946777A1 (en) 2007-01-16 2007-01-16 Substituted pyrazoline for preventing weight gain

Publications (2)

Publication Number Publication Date
ES2330071A1 ES2330071A1 (en) 2009-12-03
ES2330071B1 true ES2330071B1 (en) 2010-07-05

Family

ID=41327361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200800079A Expired - Fee Related ES2330071B1 (en) 2007-01-15 2008-01-14 COMBINATION OF ACTIVE SUBSTANCES.

Country Status (1)

Country Link
ES (1) ES2330071B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
FR2882931A1 (en) * 2005-03-14 2006-09-15 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US20060189658A1 (en) * 2004-02-17 2006-08-24 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
FR2882931A1 (en) * 2005-03-14 2006-09-15 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOBSHTIS, N. et al. "{}Antidepressant-induced undesirable weigth gain: Prevention with rimonabant without interference with behavioral effectiveness"{}. European Journal of Pharmacology 2007, Volumen 554, páginas 155-163. [Disponible en línea el 19 de Octubre de 2006]. Ver página 155, resumen. *
LANGE, J.H.M. & KRUSE, C.G. "{}Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists"{}. Drug Discovery Today 2005, Volumen 10, Número 10, páginas 693-702. Ver página 696, columna 1, párrafo 4 - página 697, columna 2, párrafo 2; página 699, figura 4; página 700, columna 2, párrafo 2. *
LANGE, J.H.M. et al. "{}Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists"{}. Journal of Medicinal Chemistry 2005, Volumen 48, páginas 1823-1838. Ver página 1823, resumen; página 1824, figura 1; página 1828, columna 2. *

Also Published As

Publication number Publication date
ES2330071A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
GT200600445A (en) SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF THE ACTIVE PRINCIPLE.
UY30373A1 (en) PHENYLALANINE DERIVATIVES, PREPARATION PROCEDURES AND APPLICATIONS
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
ECSP11011456A (en) NEW VIRAL REPLICATION INHIBITORS
PA8849701A1 (en) PHARMACEUTICAL DOSAGE FORM INCLUDING NIFEDIPINO OR NISOLDIPINO AND AN ANGLONENSIST OF ANGLOTENSIN II AND / OR A DIURETIC
EA201200937A1 (en) SOLID MEDICINE FORM TICAGRELOR
CR11455A (en) NEW CYCL HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES
ECSP13012467A (en) USE OF BINDERS TO MANUFACTURE STORAGE FORMULATIONS TO STORAGE
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
CL2007003289A1 (en) COMPOUNDS DERIVED FROM BICICLOCARBOXIAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES CAUSED BY THE HYPERACTIVATION OF THE VC1 RECEPTOR AS A PAIN, BLADDER DISEASE, INFLAM
BR112012028656A2 (en) combination of active loaded granules with additional assets
ES2425315R1 (en) Pharmaceutical composition and its use to prepare a medicine for the symptomatic treatment of a respiratory disease or condition
NI201200157A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING HYDROMORPHONE AND NALOXONE
GT201400059A (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
UY31922A (en) COMPOUNDS
BR112012028788A2 (en) manufacture of granules without assets
DOP2012000279A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
NI201000189A (en) SOLID MEDICINE FORMULATION WITH DELAYED RELEASE.
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
ES2524385R1 (en) Pharmaceutical composition and its use to prepare a medicine for the treatment and prevention of HIV diseases
CL2015002466A1 (en) Organic compound formulations
ES2415029A8 (en) Pharmaceutical composition and use of an antibody to prepare a medicament intended to inhibit the production or amplify the elimination of the P24 protein.
CR11734A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
CL2012000797A1 (en) Compounds derived from pyrazole, modulators of stearoyl-coa-desaturase; pharmaceutical composition comprising them; and its use for the treatment of a disease or condition such as metabolic syndrome, diabetes, insulin resistance, diabetic complications, and body weight disorders.
PA8852301A1 (en) TETRAHIDROPIRAN ESPIRO PIRROLIDINONA AND PIPERIDINONA SUBSTITUTED, ITS PREPARATION AND THERAPEUTIC USE

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20091203

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2330071B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20161207